New guidance on the use of drug-eluting stents for treating coronary vessel stenosis is intended to minimize a small but significant increased risk of stent thrombosis and death. Still, some experts voice concerns about the long-term safety of these devices.
The new advice for preventing thrombosis extends the recommendation for dual antiplatelet therapy (aspirin plus a thienopyridine such as clopidogrel) from the current 3 or 6 months (based on stent type) to 12 months. The guidance comes from three bodies, each with a slightly different perspective on the drug-eluting stent controversy.
Mitka M. Heart Groups Issue Advisories for Reducing Drug-Eluting Stent Risks. JAMA. 2007;297(8):797-798. doi:10.1001/jama.297.8.797